CSIMarket
 


Stemline Therapeutics Inc  (STML)
Other Ticker:  
 

Stemline Therapeutics Inc's Tangible Leverage Ratio

STML's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


In Spite of the repayements of liabilities of -1.7%, in I Quarter 2020 ,Tangible Leverage Ratio deteriorated to 0.16, below the Stemline Therapeutics Inc's average Tangible Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the first quarter 2020, 110 other companies have achieved lower Tangible Leverage Ratio than Stemline Therapeutics Inc in the I Quarter 2020. While Tangible Leverage Ratio total ranking has deteriorated compared to the forth quarter 2019 from 191 to 331 .

Explain Tangible Leverage Ratio?
What is STML Market Share?
What are STML´s Total Liabilities?


STML Tangible Leverage Ratio (Mar 31 2020)
I. Quarter
(Dec 31 2019)
IV. Quarter
(Sep 30 2019)
III. Quarter
(Jun 30 2019)
II. Quarter
(Mar 31 2019)
I. Quarter
Y / Y Tangible Equity Change 35.59 % 287.7 % 176.11 % 23.89 % 23.72 %
Y / Y Total Liabilities Change -15.8 % 9.73 % 30.45 % 49.06 % 38.74 %
Tangible Leverage Ratio MRQ 0.16 0.14 0.13 0.27 0.25
STML's Total Ranking # 331 # 191 # 278 # 252 # 460
Seq. Tangible Equity Change -9.76 % -6.74 % 74.06 % -7.44 % 158.03 %
Seq. Total Liabilities Change -1.7 % 2.77 % -16.91 % 0.31 % 28.09 %



Tangible Leverage Ratio first quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 111
Healthcare Sector # 166
Overall Market # 331


Tangible Leverage Ratio Statistics
High Average Low
0.5 0.16 0.03
(Dec 31 2018)   (Sep 30 2013)




Financial Statements
Stemline Therapeutics Inc's Tangible Equity $ 148 Millions Visit STML's Balance sheet
Stemline Therapeutics Inc's Total Liabilities $ 23 Millions Visit STML's Balance sheet
Source of STML's Sales Visit STML's Sales by Geography


Cumulative Stemline Therapeutics Inc's Tangible Leverage Ratio

STML's Tangible Leverage Ratio for the trailling 12 Months

STML Tangible Leverage Ratio

(Mar 31 2020)
I. Quarter
(Dec 31 2019)
IV. Quarter
(Sep 30 2019)
III. Quarter
(Jun 30 2019)
II. Quarter
(Mar 31 2019)
I. Quarter
Y / Y Tangible Equity TTM Growth 35.59 % 287.7 % 176.11 % 23.89 % 23.72 %
Y / Y Total Liabilities TTM Growth -15.8 % 9.73 % 30.45 % 49.06 % 38.74 %
Tangible Leverage Ratio TTM 0.16 0.18 0.23 0.3 0.28
Total Ranking TTM # 8 # 340 # 396 # 284 # 9
Seq. Tangible Equity TTM Growth -9.76 % -6.74 % 74.06 % -7.44 % 158.03 %
Seq. Total Liabilities TTM Growth -1.7 % 2.77 % -16.91 % 0.31 % 28.09 %


On the trailing twelve months basis Due to repayements of liabilities of -1.7% Stemline Therapeutics Inc decreased Tangible Leverage Ratio in the 12 months ending in I Quarter 2020 to 0.16, below the company's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 110, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than Stemline Therapeutics Inc. While Tangible Leverage Ratio total ranking has improved so far to 8, from total ranking in previous 12 month period at 340.

Explain Tangible Leverage Ratio?
What is STML Market Share?
What are STML´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 111
Healthcare Sector # 166
Within the Market # 8


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
0.5 0.16 0.03
(Dec 31 2018)   (Sep 30 2013)




Companies with similar Tangible Leverage Ratio in the quarter ending Mar 31 2020, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioMar 31 2020 MRQ Total LiabilitiesMar 31 2020 MRQ Tangible Equity
Viracta Therapeutics Inc   0.43 $ 9.401  Millions$ 22.086  Millions
Tetraphase Pharmaceuticals Inc  0.42 $ 9.898  Millions$ 23.295  Millions
Rezolute Inc   0.42 $ 4.375  Millions$ 10.302  Millions
Global Blood Therapeutics Inc.  0.42 $ 217.574  Millions$ 523.572  Millions
Intec Pharma Ltd   0.41 $ 5.769  Millions$ 14.220  Millions
Spectrum Pharmaceuticals Inc   0.40 $ 62.224  Millions$ 153.768  Millions
Ardelyx Inc   0.40 $ 67.565  Millions$ 167.757  Millions
Arbutus Biopharma Corp  0.40 $ 29.358  Millions$ 73.256  Millions
Macrogenics Inc   0.39 $ 74.840  Millions$ 190.573  Millions
Oncolytics Biotech Inc   0.39 $ 7.348  Millions$ 18.961  Millions
Phasebio Pharmaceuticals Inc.  0.37 $ 20.043  Millions$ 53.486  Millions
United Therapeutics Corporation  0.37 $ 1,045.400  Millions$ 2,790.200  Millions
Savara Inc   0.37 $ 32.659  Millions$ 87.316  Millions
Equillium Inc   0.37 $ 13.565  Millions$ 36.346  Millions
Kintara Therapeutics Inc   0.37 $ 1.382  Millions$ 3.717  Millions
Bridgebio Pharma Inc   0.36 $ 163.180  Millions$ 449.018  Millions
Kineta Inc   0.35 $ 18.770  Millions$ 53.140  Millions
Beyondspring Inc   0.35 $ 30.413  Millions$ 86.625  Millions
Siga Technologies Inc  0.35 $ 30.432  Millions$ 87.244  Millions
Fulcrum Therapeutics Inc   0.34 $ 24.225  Millions$ 70.631  Millions
Epizyme Inc.  0.34 $ 108.141  Millions$ 315.615  Millions
Cue Biopharma Inc   0.34 $ 15.413  Millions$ 45.236  Millions
Rocket Pharmaceuticals Inc   0.34 $ 86.700  Millions$ 255.236  Millions
Blueprint Medicines Corporation  0.34 $ 230.692  Millions$ 682.931  Millions
Arvinas Inc   0.33 $ 70.743  Millions$ 211.707  Millions
Trevena inc   0.33 $ 9.613  Millions$ 28.795  Millions
Orphazyme A  0.33 $ 201.968  Millions$ 620.525  Millions
Qualigen Therapeutics Inc   0.32 $ 1.602  Millions$ 5.015  Millions
Acer Therapeutics Inc   0.32 $ 2.051  Millions$ 6.442  Millions
Kadmon holdings inc   0.32 $ 43.011  Millions$ 135.186  Millions

Date modified: 2023-03-23T19:55:21+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com